The study was nested within a larger modeling project examining inequalities in cardiovascular outcomes between 1999 and 2007.
N umerous studies have examined socioeconomic differences in incidence, prevalence, mortality, and risk factors for coronary heart disease (CHD). 1 However, studies on CHD treatment are limited in number, size of population, method of classifying socioeconomic circumstances (SECs), range of treatment examined, contemporariness, and crucially, trends over time. This paucity of evidence reflects the limited ability of several international healthcare systems to link medication and SEC data. Furthermore, much of the evidence derives from the United States, [2] [3] [4] where private medicine, insurance, and payment mechanisms inevitably generate socioeconomic treatment gradients. In the United Kingdom, access to and use of National Health Service care is universal. Treatment of CHD should therefore be equitable, based solely on clinical need, regardless of ability to pay, age, sex, or other social factors. However, evidence from the United Kingdom has been limited to small cohort studies in England [5] [6] [7] or data from primary care in Scotland. 8, 9 The extent to which the National Health Service is delivering equitable CHD care is thus uncertain.
Four key medical therapies substantially reduce morbidity and mortality in patients with CHD: antiplatelet agents, β-blockers, statins, and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). We undertook a cross-sectional observational analysis of nationally representative primary and secondary care data from the United Kingdom. The primary objective was to examine secular trends in the use of key medical therapies since 1999 across a broad spectrum of coronary disease presentations, stratified by SEC.
The latter date was chosen to provide the most contemporary data available from a wide range of sources. Socioeconomic status was defined using the UK government's Index of Multiple Deprivation 2007 (IMD), described in detail in Methods in the online-only Data Supplement. 10 This is a composite measure of relative deprivation at small area level (termed Lower Super Output Areas [LSOA]) covering an average population of 1500 people. The IMD is conceptualized as a weighted area-level aggregation of distinct dimensions of deprivation that are measured separately. The area is characterized as deprived relative to other areas based on the proportion of people experiencing each particular dimension of deprivation living in that area and the single deprivations combined. The experience of the population in an area thus gives the area its deprivation characteristics.
The overall index aggregates 38 indicators covering 7 dimensions of deprivation, weighted as follows ( Table I in the online-only Data  Supplement) : income, 22.5% (the proportion of individuals experiencing income deprivation); employment, 22.5% (involuntary exclusion of the working age population from work); health and disability, 13.5% (premature mortality, morbidity, and disability); education, 13.5% (deprivation in education attainment, skills, and training); barriers to housing and services, 9.3% (geographical and wider barriers to housing and key local services); crime, 9.3% (rate of 4 major recorded crime types); and living environment, 9.3% (quality of local indoor and outdoor environment). Deprivation indices predating IMD, such as the Carstairs Index and Townsend Index, were compiled at the geographical level of electoral wards based solely on Census data. By contrast, the IMD combines census information with regularly updated administrative data during the intercensal period. These include returns to government departments (Work and Pensions; Her Majesty's Revenue and Customs; Children, Schools and Families; Communities and Local Government; Office for National Statistics) and nongovernmental agencies (National Asylum Support Service; Prescribing Pricing Authority; Crime and Disorder Reduction Partnership; Higher Education Statistics Agency).
Different techniques are used to obtain a single summary measure for each domain. When indicators are nonoverlapping with identical underlying metrics, they are summed and divided by the population at risk to create an area rate. When a simple rate is not possible, appropriate weights are derived using maximum likelihood factor analysis to permit combination of indicators. A set of individual Domain Indices is obtained, each with different units of measurement. The 7 Domain Indices are then assigned a national rank among the 32 482 LSOAs in England. The most deprived LSOA is ranked 1, and the least deprived is ranked 32 482. These are then combined into an overall IMD using exponential transformation of the ranks.
The IMD is suited to measuring change over time as the LSOA boundaries remain fixed over time unlike electoral wards. The smaller mean population compared with electoral wards (typically 1500 as opposed to 6000 people) improves the population homogeneity and reduces grouping of residents with differing levels of deprivation. 11 The 32 482 LSOAs in England were ranked in ascending order of deprivation score and grouped in equal fifths, quintiles 1 and 5 (IMDQ1 and IMDQ5), representing the least and most deprived areas, respectively. The postcode address of individual patients was linked to the LSOA and hence the corresponding deprivation quintile. Although lack of deprivation does not necessarily equate to affluence, to assist readability, we refer to quintile 1 as most affluent and quintile 5 as most deprived.
Patient Groups
Three patient cohorts were defined: myocardial infarction, secondary prevention, and stable angina (Table) . The first included all patients aged 25 years or older with ST-segment-elevation and non-STsegment-elevation myocardial infarction (n=51 755) discharged from hospital in England and Wales in 2003 and 2007. The proportions of patients receiving each therapy were obtained from the Myocardial Ischemia National Audit Project (MINAP) and applied to counts from Hospital Episode Statistics, which records every inpatient care episode to National Health Service hospitals in the United Kingdom. MINAP provides a secure electronic data system that uploads encrypted patient information to the central cardiac audit database. 12 The baseline year of 2003 was selected as the first year of complete national coverage of acute care hospitals by MINAP. The returning hospital diagnosed myocardial infarction according to locally agreedon electrocardiographic and biochemical criteria. 13 ST-segment-elevation and non-ST-segment-elevation acute coronary syndrome data were aggregated because of clinical and therapeutic similarity, after initial analysis revealed no significant differences in age, sex, or socioeconomic treatment gradients. Medication use was defined as receiving the drug in hospital (orally or intravenously).
Patients cohorts with previous myocardial infarction or coronary revascularization meriting secondary prevention (n=32 976 in 2007), and patients with angina but without previous myocardial infarction (n=33 211) were obtained from the UK General Practice Research Database (GPRD). The GPRD is the world's largest longitudinal
WHAT IS KNOWN
• Studies in the United States have demonstrated inequalities in the prescription of key medical therapies that reduce morbidity and mortality in patients with coronary heart disease. • Previous studies of treatment equity in universal healthcare systems have been limited in the range of treatments examined, method of classifying socioeconomic circumstances, and ability to detect changes over time.
WHAT THE STUDY ADDS
• The UK National Health Service is delivering equitable treatment independently of socioeconomic circumstances across a broad range of therapies. • Prescriptions rates in primary care have improved markedly; β-blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for secondary prevention and treatment of angina have doubled, from ≈30% to >60%. database of anonymized primary care records linked with morbidity and prescribing information. 14 Several studies have confirmed the validity of diagnostic and prescription data in the GPRD, [14] [15] [16] particularly for myocardial infarction and stroke. 17 
Treatment Rates and Standardization
Drug treatment in the calendar year of interest was identified using Multilex drug codes, which can be mapped to the British National Formulary classification. Levels therefore relate to prescriptions issued and recorded by general practitioners and not to prescriptions dispensed. Age-and sex-specific rates were directly standardized to the European Standard Population using 10-year age bands to age 85 and over. Standard errors for medication use among myocardial infarction patients were calculated using individual-level data with the Primary Care Trust specified as a clustering variable to account for similarities between patients living in the same locality. Standard errors for the post-myocardial infarction/revascularization and angina estimates were computed on aggregate data using the Poisson approximation. 18 Standardized rate ratios and associated 95% confidence intervals were calculated by comparing directly age-standardized rates from the most and least deprived quintiles. To assist clarity, we report all rates in absolute terms (percentages) and all change or comparison of rates as rate ratios (RRs).
Results

Change and Absolute Levels of Treatment
Acute treatments of myocardial infarction were already widely practiced in 2003, and relatively small improvements occurred by 2007 ( Figure 1 ; Table III All aspects of secondary prevention after myocardial infarction or coronary revascularization increased significantly between 1999 and 2007 ( Figure 1 ; Table IV Relative increases were even more marked for treatment of angina, although absolute treatment levels remained much lower than for secondary prevention (Figure 1 
Socioeconomic Inequality
Overall, combining men and women of all ages, no significant socioeconomic gradients were apparent in either treatment of acute myocardial infarction or secondary prevention ( Figure  1 ; Tables III and IV Socioeconomic inequality in young (<55 years), middle-aged (55-74 years), and elderly (≥75 years) men and women was then examined. Again, no consistent gradients were observed for any individual treatment of either acute myocardial infarction or secondary prevention (Figures 2 and 3) . Higher treatment levels for angina in the most deprived quintile were again present to various degrees in both men and women for all 3 therapies ( Figure 4 ; Table V in the online-only Data Supplement). The gradient was most pronounced in young patients, with some spillover into the middle-aged. In those <55 years, use of aspirin, ACEI/ARB, and statins in the most deprived was approximately twice that in the most affluent patients.
Age Inequality
Elderly patients with acute myocardial infarction or requiring secondary prevention received less treatment in the baseline year (Figures 2 and 3 ). This inequality was most pronounced for β-blockers and statins. The small overall improvements in treatment of acute myocardial infarction and marked progress in secondary prevention generally served to reduce these inequalities, lessening disparities between age bands by 2007. However, small age gradients persisted for β-blockers and statins. The opposite trend was apparent for angina, with the young rather than the elderly receiving less treatment (Figure 4 ).
Sex Inequality
No consistent sex differences were apparent in the treatment of acute myocardial infarction for any age group or in secondary prevention and the treatment of angina among middle-aged and elderly patients (Figures 2-4 ). However, in younger women (<55 years) requiring secondary prevention or with angina, prescribing rates for all therapies were ≈10% lower compared to men (Figures 3 and 4 ).
Discussion
The UK National Health Service is generally delivering equitable cardiovascular treatment, independently of SECs and sex. This study represents a success for the community management of CHD. In just 8 years, use of secondary prevention therapies approximately doubled (ACEI/ARB, β-blocker, and statin), and survival-enhancing therapy for angina tripled (ACEI/ARB and statins). The UK Department of Health defines macro-level policy through the National Service Framework. In 2000, the National Service Framework set national standards for prevention, diagnosis, treatment, rehabilitation, and outcomes for CHD, along with milestones to measure progress. 19 The prioritization of CHD in government provided additional resources and promoted national initiatives such as MINAP. The National Institute for Clinical Excellence was concurrently instituted in 1999 to reduce variation in the availability and quality of care. National Institute for Clinical Excellence guides micro-level policy through evidence-based clinical and public health guidelines, technology appraisals, quality standards, and implementation tools. The National Institute for Clinical Excellence Quality and Outcomes Framework program was introduced in 2004 to incentivize performance in primary care and includes multiple domains and indicators for CHD. Together, these initiatives have spearheaded efforts to reduce cardiovascular mortality by 40% within a decade. 19 
Change and Absolute Levels of Treatment
Inpatient treatment is generally good and comparable to international registries, with antiplatelet prescribing close to maximum. 20 Nevertheless, levels of ACEI/ARB (75%) and β-blockers (73%) are lower than the rates achieved at discharge in selected Scandinavian and Eastern European countries, which exceed 85%. 20 The decline in β-blockade is worrisome and may reflect the expansion of primary percutaneous intervention and the misconception that only patients with impaired ventricular function require β-blockers. 21 International guidelines are unanimous in endorsing β-blockers for all patients with myocardial infarction. 22, 23 In the 1999 EUROASPIRE II survey of secondary prevention, the United Kingdom had the lowest rates of β-blockade and among the lowest use of ACEIs in Europe. 24 Results of the 2006 EUROASPIRE III survey were very different. 20 Although prescribing of ACEI/ARB improved to the forefront of European countries, use of β-blocker increased but remained suboptimal. However, findings were based only on interviews in a relatively small patient cohort (n=399). We have now corroborated these improvements using a validated and nationally representative data set. Our results also extend previous analysis from the UK DIN-LINK primary care database, 25 confirming continued improvement in secondary prevention up to 2007. Nevertheless, β-blocker and ACEI/ARB rates of 55% to 60% still fall short of the National Service Framework target of 80% for secondary prevention. 26 Achieving these simple targets could result in some 20 000 fewer CHD deaths annually in the United Kingdom. 27 Relative increases in secondary prevention for patients with angina were likewise impressive, most notably the 3-fold increase in ACEI/ARB and statins. However, as observed in the DIN-LINK analysis, 25 medication rates remain twice as high in patients with more reliable diagnoses (myocardial infarction or revascularization) compared with those with angina. 26 This is unacceptable given that long-term mortality in patients with angina is very similar to that of myocardial infarction survivors. 28 Diagnosing angina also has far-reaching implications for treatment, health or life insurance, patient and family stress, and self-imposed lifestyle restrictions. The diagnosis should therefore be confirmed or refuted whenever possible and should be accompanied by prescription of survival-enhancing medications. These therapies are cheap with irrefutable benefits, and serious adverse effects are rare.
Socioeconomic Inequality
Reassuringly, no socioeconomic gradients were apparent in the treatment of acute myocardial infarction for any age group in men or women. Although overall treatment levels were good but not ideal, the equality of treatment for deprived patients is a clear success. In the United States, cohort studies have consistently demonstrated inequalities in the prescription of aspirin, 2-4 ACE inhibitors, 4 and β-blockers for patients with acute myocardial infarction. [2] [3] [4] By contrast, very little inequality was apparent in small cohorts from the United Kingdom, Italy, and France. 5, 29, 30 The disparity highlights the health benefits of universal healthcare.
We detected no significant inequalities in allocation of secondary prevention for any age group in men or women. Earlier studies largely originated in Europe. Most simply stratified SECs according to occupation, 6,7,31-33 and only 1 study used a composite measure of deprivation. 8 In 14 435 Scottish primary care patients in 2002, the adjusted odds of receiving treatment was unaffected by deprivation quintile (as measured using the Carstairs score). 8 Our analysis builds on these reports, with the larger population allowing more precise estimates when stratified by sex and age bands. No major differences in secondary prevention were found.
Few studies have investigated socioeconomic differences in patients with the softer diagnosis of angina. 9 Gradients for all therapies unexpectedly demonstrated greater use in the most deprived. When disaggregated, this trend originated among younger deprived patients in whom use of aspirin, ACEI/ARB, and statins was approximately twice that in the most affluent. A number of explanations are plausible. Concomitant indications for medical therapy may cluster in deprived younger patients. Physicians may also perceive deprived patients to be at greater cardiovascular risk than their affluent counterparts.
Age Inequality
We observed some undertreatment of elderly patients across all CHD diagnoses, particularly with β-blockers and statins, which improved over time. Age inequalities in the treatment of cardiovascular disease are common in both the United States and Europe [34] [35] [36] [37] and may in part relate to increasing comorbidity and contraindications, which we were unable to assess in this data set. Nevertheless, previous studies have demonstrated age inequalities that are independent of eligibility, 34, 36 and unless this reflects explicit informed patient choice, ageism remains a concern. The recent UK Equality Act (2010) included a provision to ban age discrimination in public services, which has been be enforced throughout the National Health Service since October 2012. The hope is that this will ameliorate undertreatment when not related to patient choice. 
Sex Inequality
Few consistent sex differences were observed for hard diagnoses (myocardial infarction and postrevascularization). The finding of equitable inpatient care is consistent with the EUROASPIRE III survey and National Registry of Myocardial Infarction. 38, 39 Prior reports from primary care in the United Kingdom have revealed significant sex inequalities in the secondary prevention of CHD. 8, 40 Our age-stratified analysis suggests that this less intensive treatment was confined to younger women. Perhaps reflecting misperceived low risk, this inequality is concerning in patients with established coronary artery disease.
Similar sex inequalities were also detected in younger patients with angina, corroborating reports from primary care and the Euro Heart Survey of Stable Angina. 9, 41, 42 There are numerous potential explanations in this softer diagnosis. Women with angina are less likely to receive noninvasive or invasive investigations or to have obstructive coronary disease. 42 The resulting uncertainty is compounded by physician prejudices, 43 sex differences in symptomatology, 44 and misperceived lower risk in women. 45 Potential strategies to address the Yentl syndrome 46 include greater education among physicians and the public, ascribing sex-based targets to primary and secondary care, and guidelines that mandate objective assessment of risk and investigations (eg, National Institute for Health and Clinical Excellence 2010 guidance on the assessment and diagnosis of chest pain). 47
Strengths and Limitations
Our study accurately describes changing treatment for a broad spectrum of coronary disease presentations in both primary and secondary care using nationally representative data sources and a validated index of deprivation. The large sample size permits precise estimates, even when stratified by SECs, age, and sex. The available data set, and hence our ability to adjust for confounding, was limited in terms of comorbidities and contraindications to therapy. However, this has limited relevance when examining equality of treatment once coronary artery disease is established. Every individual is by definition high risk and should receive every therapy unless contraindicated. To the best of our knowledge, there is little evidence of significant socioeconomic gradients in genuine contraindications to therapy (eg, end-stage renal disease, severe aortic stenosis, severe asthma/chronic obstructive pulmonary disease, heart block, significant liver disease). 48 Area-based categorization of SEC assumes homogeneity within a geographical area. Although individual-and arealevel measures make independent contributions to health outcomes, 49 composite measures correlate reasonably with individual socioeconomic position and also help to capture the contextual effects of living conditions. 50 Finally, community treatment was defined by prescriptions issued rather than dispensed. Medication receipt and compliance were therefore not assessed.
As with all population studies of angina, our analysis relies on the ascribed physician diagnosis, which may not be supported by objective investigations. 9, 41 The estimates for angina treatment in the youngest age band derive from the smallest sample size, with a degree of imprecision visible in the inconsistent fluctuation between IMD quintiles. Nevertheless, all point estimates for each therapy in every quintile were consistently far lower than anticipated. The data extraction was replicated, results were repeatedly analyzed and standardized against 2 different populations, and GPRD was contacted to investigate and verify the findings. No errors were detected, suggesting that these results accurately reflect real-life practice.
Conclusions
We found no evidence of systematic or persistent socioeconomic inequalities in the treatment of coronary artery disease across the United Kingdom. Although reassuring, there is no room for complacency. Treatment levels still fall short of national targets and best-practice cohorts. Even modest treatment inequalities in younger women and the elderly are concerning, particularly given the greater absolute benefits realized in older patients. Nevertheless, in just 8 years, secondary prevention after myocardial infarction or revascularization has doubled and therapies in patients with angina have tripled. Future strategies should aim to further increase overall treatment levels and to eradicate remaining age and sex inequalities.
